Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma

JAMA Oncology

Volumn 1, Issue 6, 2015, Pages 746-754

  Korde, Neha ^a,b   Roschewski, Mark ^a   Zingone, Adriana ^a   Kwok, Mary ^a   Manasanch, Elisabet E ^a   Bhutani, Manisha ^a   Tageja, Nishant ^a   Kazandjian, Dickran ^a   Mailankody, Sham ^a   Wu, Peter ^a   Morrison, Candis ^a   Costello, Rene ^a   Zhang, Yong ^a   Burton, Debra ^a   Mulquin, Marcia ^a   Zuchlinski, Diamond ^a   Lamping, Liz ^a   Carpenter, Ashley ^a   Wall, Yvonne ^a   Carter, George ^a   Cunningham, Schuyler C ^a   Gounden, Verena ^c   Sissung, Tristan M ^d   Peer, Cody ^e   Maric, Irina ^d   Calvo, Katherine R ^d   Braylan, Raul ^d   Yuan, Constance ^d   Stetler Stevenson, Maryalice ^f   Arthur, Diane C ^d   Kong, Katherine A ^d   Weng, Li ^d   Faham, Malek ^d   Lindenberg, Liza ^d   Kurdziel, Karen ^d   Choyke, Peter ^c   Steinberg, Seth M ^d   Figg, William ^c   Landgren, Ola ^a,b   more..

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e LEVINE CANCER INSTITUTE   (United States)

^f Sequenta Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARFILZOMIB; DEXAMETHASONE; LENALIDOMIDE; OLIGOPEPTIDE; PROTEASOME INHIBITOR; THALIDOMIDE; TUMOR MARKER;

ADULT; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MORTALITY; MULTIPLE MYELOMA; NATIONAL HEALTH ORGANIZATION; PILOT STUDY; RISK FACTOR; TIME; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MARYLAND; MIDDLE AGED; MULTIPLE MYELOMA; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASM, RESIDUAL; OLIGOPEPTIDES; PILOT PROJECTS; PROTEASOME INHIBITORS; RISK FACTORS; THALIDOMIDE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84965094838     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.2010     Document Type: Article

References (24)

1. Bolli N, Avet-Loiseau H, Wedge DC, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997.
2. de Mel S, Lim SH, Tung ML, Chng WJ. Implications of heterogeneity in multiple myeloma. BioMed Res Int. 2014;2014:232546.
3. Egan JB, Shi CX, Tembe W, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012;120 (5):1060-1066.
4. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12(5):335-348.
5. Walker BA, Wardell CP, Melchor L, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia. 2014; 28(2):384-390.
6. LoRusso PM, Canetta R, Wagner JA, et al. Accelerating cancer therapy development: the importance of combination strategies and collaboration. Summary of an Institute of Medicine workshop. Clin Cancer Res. 2012;18(22):6101-6109.
7. Roschewski M, Korde N, Wu SP, Landgren O. Pursuing the curative blueprint for early myeloma. Blood. 2013;122(4):486-490.
8. Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120(9):1801-1809.
9. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5): 679-686.
10. Stewart AK, Rajkumar SV, Dimopoulos MA, et al; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2): 142-152.
11. Paiva B, Vidriales M-B, Cerveró J, et al; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112(10):4017-4023.
12. Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013;31(20):2540-2547.
13. Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123(20):3073-3079.
14. Mailankody S, Korde N, Lesokhin AM, et al. Minimal residual disease in multiple myeloma: bringing the bench to the bedside [published online ahead of print January 27, 2015]. Nat Rev Clin Oncol. doi:10.1038/nrclinonc.2014.239.
15. Ladetto M, Brüggemann M, Monitillo L, et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia. 2014;28(6): 1299-1307.
16. Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011; 118(23):5989-5995.
17. Rajkumar SV, Harousseau JL, Durie B, et al; International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691-4695.
18. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26): 2609-2617.
19. Faham M, Zheng J, Moorhead M, et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2012;120(26):5173-5180.
20. Perez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110:2586-2592.
21. Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111:785-789.
22. Mateos MV, Hernández MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013; 369(5):438-447.
23. Flanders A, Stetler-Stevenson M, Landgren O. Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. Blood. 2013;122(6):1088-1089.
24. Landgren O, Gormley N, Turley D, et al. Flow cytometry detection of minimal residual disease in multiple myeloma: lessons learned at FDA-NCI roundtable symposium. Am J Hematol. 2014;89 (12):1159-1160.